サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：細胞・遺伝子治療用ドラッグデリバリーデバイス市場-世界の産業規模、シェア、動向、機会、2018年～2028年予測
市場調査レポート
商品コード
1321036

細胞・遺伝子治療用ドラッグデリバリーデバイス市場-世界の産業規模、シェア、動向、機会、2018年～2028年予測

Cell & Gene Therapy Drug Delivery Devices Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Commercialized Drugs, By Route of Administration, By Method, By Region and Competition

出版日
ページ情報
英文 110 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

細胞・遺伝子治療用ドラッグデリバリーデバイス市場-世界の産業規模、シェア、動向、機会、2018年～2028年予測
出版日: 2023年08月01日
発行: TechSci Research
ページ情報: 英文 110 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の細胞・遺伝子治療用ドラッグデリバリーデバイス市場は、予測期間2024～2028年に力強い成長を示すと予想されます。

この背景には、がんなどの様々な慢性疾患の治療における細胞・遺伝子治療の利用が拡大していることがあります。細胞治療や遺伝子治療中の薬剤投与量を効率的にモニタリングできるドラッグデリバリーデバイスに対する需要の高まりが、今後数年間の市場成長を支えるものと期待されます。

慢性疾患の有病率の増加

人口の間でがんの有病率が憂慮すべき割合で増加しており、効果的な治療法への要求が様々な細胞・遺伝子治療の開発に繋がっています。細胞・遺伝子治療の開発は、それらを提供するために使用されるさまざまなデバイスの需要の増加につながり、それによって細胞・遺伝子治療用ドラッグデリバリーデバイスの世界の成長を推進しています。Globocan 2020によると、世界中で新たに報告されたがんの症例は約19,292,789件です。そのうち10,065,305人が男性で、肺がん、前立腺がん、大腸がん、胃がん、肝臓がんで占められています。同様に、女性で報告された新規がん症例数は約9,227,484例で、乳がん、大腸がん、肺がん、子宮頸がん、甲状腺がんが最も多いです。

細胞・遺伝子治療と臨床試験に関するFDA承認の増加

2017年に最初の治療法が承認され、細胞・遺伝子治療は投資の世界では比較的新しいものです。Cell and Gene Journalによると、FDAが承認した22の細胞・遺伝子治療のうち、14は臍帯血ベースの治療法です。残りの承認は、2つの遺伝子療法、7つの細胞療法、5つの改変細胞療法です。また、承認された340の生物製剤のうち、細胞・遺伝子治療は全体のわずか7％です。また、2021年にFDAが承認した50以上の医薬品のうち、細胞・遺伝子治療はわずか2つです。2021年に承認された医薬品全体に占める割合は少ないが、承認された細胞・遺伝子治療薬が10％増加したことを反映しており、医学の発展における目覚ましい一歩です。このように、より優れたドラッグデリバリーデバイスを提供する最新の発売に対するFDAの承認数の増加は、細胞および遺伝子療法を提供するために使用されるデバイスの開発のための様々な企業の間で人気を集めています。このことは、今後数年間、世界の細胞・遺伝子治療用ドラッグデリバリーデバイス市場の成長を後押しすると予想されます。

細胞・遺伝子治療市場への投資と資金調達の増加

細胞・遺伝子治療の会社は、民間および公的な投資から優れた金額と比率を得ています。治療法が確立されていない疾患や慢性疾患をターゲットとする新規細胞・遺伝子治療の保証は、民間投資、新規株式公開、企業からの多額の資金流入につながっています。ライフ・サイエンスへの民間投資の増加に伴い、細胞・遺伝子治療への投資も急増しています。Cell and Gene Journal誌によると、2010年から2021年にかけての投資成長率は、遺伝子治療が59％であるのに対し、細胞治療は63％であり、これはより高い成長率であると同時に、予測期間中に世界の細胞・遺伝子治療用ドラッグデリバリーデバイス市場の成長を後押しする重要な役割をもたらすと予想されています。

また、いくつかの国の様々な政府は、患者や医師の間でデバイスに関する認識を高めるプロセスを支援しており、それによって細胞・遺伝子治療用ドラッグデリバリーデバイスの世界市場の成長をサポートしています。

市場セグメンテーション

細胞・遺伝子治療用ドラッグデリバリーデバイスの世界市場は、タイプ、商品化された薬剤、投与経路、方法、地域によって細分化されます。タイプ別では、網膜下注入カニューレ、延長チューブ、静脈内カテーテル、滅菌インスリン注射器、プレフィルドシリンジ、輸液バッグに細分化されます。市販薬に基づくと、市場はさらにLuxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelisに細分化されます。投与経路によって、市場はさらに経口、静脈内、眼、経皮、その他に区分されます。投与方法の種類によって、市場は体外と生体外に区分されます。地域別に見ると、市場は北米、欧州、アジア太平洋、南米、中東・アフリカに分布しています。

市場プレイヤー

Becton, Dickinson, and Company、Novartis AG、Amgen Inc.、Kite Pharma, Inc.、Pfizer, Inc.、Bausch &Lomb Incorporated、Bluebird bio, Inc.、Castle Creek Biosciences, Inc（Fibrocell Technologies, Inc.）、Dendreon Pharmaceuticals LLC.、Helixmith Co、Ltd.（ViroMed社）、Orchard Therapeutics plc、Renova Therapeutics、Spark Therapeutics, Inc.、uniQure N.V.、Vericel Corporationなどが、世界の細胞・遺伝子治療用ドラッグデリバリーデバイス市場で事業を展開する大手企業です。

利用可能なカスタマイズ

TechSci Research社は、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

  • 市場の定義
  • 市場の範囲
    • 対象市場
    • 調査対象年
    • 主要市場セグメンテーション

第2章 調査手法

  • 調査目的
  • ベースライン調査手法
  • 主要産業パートナー
  • 主要協会と二次情報源
  • 予測手法
  • データの三角測量と検証
  • 仮定と限界

第3章 エグゼクティブサマリー

  • 市場概要
  • 主要市場セグメンテーションの概要
  • 主要市場プレーヤーの概要
  • 主要地域/国の概要
  • 市場促進要因・課題・動向の概要

第4章 顧客の声

第5章 臨床試験分析

  • 進行中の臨床試験
  • 完了した臨床試験
  • 終了した臨床試験
  • パイプラインの開発段階別内訳
  • パイプラインのステータス別内訳
  • パイプラインの内訳、試験タイプ別
  • パイプラインの地域別内訳
  • 臨床試験ヒートマップ

第6章 細胞・遺伝子治療用ドラッグデリバリーデバイスの世界市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 市販薬別
    • 投与経路別
    • 投与方法別
    • 企業別
    • 地域別
  • 市場マップ
    • タイプ別
    • 市販薬別
    • 投与経路別
    • 投与方法別
    • 地域別

第7章 アジア太平洋の細胞・遺伝子治療用ドラッグデリバリーデバイス市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 市販薬別
    • 投与経路別
    • 投与方法別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第8章 欧州の細胞・遺伝子治療用ドラッグデリバリーデバイス市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 市販薬別
    • 投与経路別
    • 投与方法別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 北米の細胞・遺伝子治療用ドラッグデリバリーデバイス市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 市販薬別
    • 投与経路別
    • 投与方法別
    • 国別
  • 北米国別分析
    • 米国
    • メキシコ
    • カナダ

第10章 南米の細胞・遺伝子治療用ドラッグデリバリーデバイス市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 市販薬別
    • 投与経路別
    • 投与方法別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの細胞・遺伝子治療用ドラッグデリバリーデバイス市場展望

  • 市場規模および予測
    • 金額ベース
  • 市場シェアと予測
    • タイプ別
    • 市販薬別
    • 投与経路別
    • 投与方法別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

  • 最近の動向
  • 合併・買収
  • 製品発表

第14章 競合情勢

  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（As Reported）
  • Recent Developments
  • SWOT Analysis
    • Becton, Dickinson, and Company
    • Novartis AG
    • Amgen Inc.
    • Kite Pharma, Inc.
    • Pfizer, Inc.
    • Bausch & Lomb Incorporated
    • Bluebird bio, Inc.
    • Castle Creek Biosciences, Inc（Fibrocell Technologies, Inc.）
    • Dendreon Pharmaceuticals LLC.
    • Helixmith Co., Ltd（ViroMed Co., Ltd）

第15章 戦略的提言

目次
Product Code: 7364

Global Cell & Gene Therapy Drug Delivery Devices market is expected to show robust growth in the forecast period, 2024-2028. This can be attributed to the growing use of cell and gene therapy for the treatment of various chronic diseases such as cancer. The increasing demand for drug delivery devices that are efficient in monitoring drug dosage during cell and gene therapies is expected to support market growth in the coming years.

Cell and Gene Therapy is a transformative industry that is emerging with efficient potential. Cell and Gene therapy includes the extraction of cells, proteins, or genetic material (DNA) from the Donor and altering them to provide highly specific and personalized therapy. The growing popularity of personalized medicine has significantly increased the demand for cell and gene therapies, thereby creating the demand for devices used to deliver these therapies.

The effective dosages help in maximizing the bioavailability of the drug at the target sites, making it convenient for the patients and thereby actively supporting the growth of devices used for delivering different therapies, including cell and gene therapies, in the coming years. Novel drug delivery systems like subdermal implants available in the market as variants such as rings and patches are anticipated to boost the global cell & gene therapy drug delivery devices market growth in the forecast period.

Increasing Prevalence of Chronic Diseases

The growing prevalence of cancer among the population at an alarming rate and the requirement for an effective treatment has led to the development of various cell and gene therapies. The development of cell and gene therapies has led to an increase in demand for different devices used to deliver them, thereby driving the growth of global cell and gene therapy drug delivery devices. According to the Globocan 2020, there are around 19,292,789 new cases of cancer reported among the population across the globe. Out of these, 10,065,305 new cancer cases were reported among males, and the most common type of cancer among them was Lung, Prostate, Colorectum, Stomach, and Liver cancer. Similarly, the number of new cancer cases reported in the female population was around 9,227,484, with breast cancer, colorectum cancer, lung cancer, cervix uteri, and thyroid cancer being the most prevalent ones.

A growing number of FDA approvals regarding Cell and Gene Therapies & Clinical Trials

With the first therapy approved in 2017, Cell therapies & Gene therapies are relatively new to the world for investments. According to the Cell and Gene Journal, out of 22 cell and gene therapies approved by the FDA, 14 are cord blood-based treatments. The remaining approvals include two gene therapies, seven cell therapies, and five modified cell therapies. Also, in total, cell & gene therapies account for just seven percent (7%) of the total 340 approved biologics. Also, of the over 50 total drugs approved by the FDA in 2021, only 2 were cell or gene therapies. Though it's a small amount of the total approved drugs in 2021, it reflects that the approved cell and gene therapies grew by 10%, which is a remarkable step in the development of medicine. Thus, the growing number of FDA approvals for the latest launches providing better drug delivery devices are gaining popularity among various companies for the development of devices used for delivering cell and gene therapies. This, in turn, is expected to bolster the growth of global cell & gene therapy drug delivery devices market in the coming years.

Increased Investment and Funding in the Cell and Gene Therapy Market

The Cell therapy & Gene therapy companies are getting an excellent amount & proportion of private and public investment. The assurance of novel cell and gene therapies which are targeting poorly treated diseases and chronic conditions has led to substantial capital flowing from private investments, initial public offerings, and corporates. With the growing private investment in life sciences, the rapid growth in investment in cell therapy and gene therapy is accountable. According to the Cell and Gene Journal, for gene therapy, the investment growth rate from 2010 to 2021 has risen to 59%, whereas for cell therapy, the investment rate has grown to 63%, which is accountable on a higher note and also anticipated for bringing a significant role in boosting the Global Cell & Gene Therapy Drug Delivery Devices Market growth during the forecast period.

Also, the various Government of several countries is aiding the process of increasing awareness about the devices among patients and doctors, thereby supporting the Global Cell & Gene Therapy Drug Delivery Devices market growth.

Market Segmentation

Global Cell & Gene Therapy Drug Delivery Devices Market can be segmented by type, commercialized drugs, route of administration, method, and region. Based on type, the market is fragmented into subretinal injection cannulas, extension tubes, intravenous catheters, sterile insulin syringes, prefilled syringe, and infusion bags. Based on the Commercialized Drugs, the market is further segmented into Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and Strimvelis. Depending on the Route of Administration, the market is further segmented into Oral, Intravenous, Ocular, Transdermal, and Others. Based on the type of method, the market can be segmented into In Vitro and Ex Vivo. Based on the regional segmentation, the market is distributed among North America, Europe, Asia- Pacific, South America, and Middle East and Africa.

Market Players

Becton, Dickinson, and Company, Novartis AG, Amgen Inc., Kite Pharma, Inc., Pfizer, Inc., Bausch & Lomb Incorporated, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Orchard Therapeutics plc, Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., Vericel Corporation, are some of the leading players operating in the global cell & gene therapy drug delivery devices market.

Report Scope

In this report, global cell & gene therapy drug delivery devices market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Cell & Gene Therapy Drug Delivery Devices Market, By Type:

  • Subretinal Injection Cannula
  • Extension Tube
  • Intravenous Catheter
  • Sterile Insulin Syringe
  • Prefilled Syringe
  • Infusion Bags

Cell & Gene Therapy Drug Delivery Devices Market, By Commercialized Drugs:

  • Luxturna
  • Kymriah
  • Yescarta
  • Zolgensma
  • Provenge
  • Strimvelis

Cell & Gene Therapy Drug Delivery Devices Market, By Route of Administration:

  • Oral
  • Intravenous
  • Ocular
  • Transdermal
  • Others

Cell & Gene Therapy Drug Delivery Devices Market, By Method:

  • In Vitro
  • Ex Vivo

Cell & Gene Therapy Drug Delivery Devices Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
  • South America
    • Brazil
    • Argentina
    • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Cell & Gene Therapy Drug Delivery Devices market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 6.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 6.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 6.2.4. By Method (In Vitro v/s Ex Vivo)
    • 6.2.5. By Company (2022)
    • 6.2.6. By Region
  • 6.3. Market Map
    • 6.3.1. By Type
    • 6.3.2. By Commercialized Drugs
    • 6.3.3. By Route of Administration
    • 6.3.4. By Method
    • 6.3.5. By Region

7. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 7.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 7.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 7.2.4. By Method (In Vitro v/s Ex Vivo)
    • 7.2.5. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Commercialized Drugs
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Method
    • 7.3.2. India Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Commercialized Drugs
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Method
    • 7.3.3. South Korea Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Commercialized Drugs
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Method
    • 7.3.4. Japan Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Commercialized Drugs
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Method
    • 7.3.5. Australia Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Commercialized Drugs
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Method

8. Europe Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 8.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 8.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 8.2.4. By Method (In Vitro v/s Ex Vivo)
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Commercialized Drugs
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Method
    • 8.3.2. Germany Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Commercialized Drugs
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Method
    • 8.3.3. United Kingdom Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Commercialized Drugs
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Method
    • 8.3.4. Italy Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Commercialized Drugs
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Method
    • 8.3.5. Spain Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Commercialized Drugs
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Method

9. North America Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 9.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 9.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 9.2.4. By Method (In Vitro v/s Ex Vivo)
    • 9.2.5. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Commercialized Drugs
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Method
    • 9.3.2. Mexico Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Commercialized Drugs
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Method
    • 9.3.3. Canada Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Commercialized Drugs
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Method

10. South America Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 10.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 10.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 10.2.4. By Method (In Vitro v/s Ex Vivo)
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Commercialized Drugs
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Method
    • 10.3.2. Argentina Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Commercialized Drugs
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Method
    • 10.3.3. Colombia Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Commercialized Drugs
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Method

11. Middle East and Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 11.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis)
    • 11.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 11.2.4. By Method (In Vitro v/s Ex Vivo)
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Commercialized Drugs
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By Method
    • 11.3.2. Saudi Arabia Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Commercialized Drugs
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By Method
    • 11.3.3. UAE Cell & Gene Therapy Drug Delivery Devices Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Commercialized Drugs
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By Method

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Company Snapshot
  • 14.3. Products & Services
  • 14.4. Financials (As Reported)
  • 14.5. Recent Developments
  • 14.6. SWOT Analysis
    • 14.6.1. Becton, Dickinson, and Company
    • 14.6.2. Novartis AG
    • 14.6.3. Amgen Inc.
    • 14.6.4. Kite Pharma, Inc.
    • 14.6.5. Pfizer, Inc.
    • 14.6.6. Bausch & Lomb Incorporated
    • 14.6.7. Bluebird bio, Inc.
    • 14.6.8. Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)
    • 14.6.9. Dendreon Pharmaceuticals LLC.
    • 14.6.10. Helixmith Co., Ltd (ViroMed Co., Ltd)

15. Strategic Recommendations